{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:37:03Z","timestamp":1793731023829,"version":"4.6.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,15]]},"abstract":"<jats:p>The introduction of tyrosine kinase inhibitors (TKIs) has revolutionized chronic myeloid leukemia (CML) treatment. The knowledge, attitude, and practice (KAP) of patients and their families play a significant role in treatment adherence and effectiveness. This study aimed to investigate the KAP of CML patients and their families regarding TKI therapy in China. From November 1 to December 31, 2022, a cross-sectional study was conducted at the Affiliated Huai\u2019an No. 1 People\u2019s Hospital in China. A total of 313 CML patients and 268 family caregivers were selected using convenience sampling. Participants answered a self-designed questionnaire. The questionnaire contained demographic\/clinical data and assessed KAP toward CML and TKI therapy. Participants exhibited mean KAP scores of 8.91 (55.7%), 33.10 (73.6%), and 2.20 (73.3%), respectively. Family members had higher knowledge and practice scores than patients (both <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05), with factors such as younger age, urban residency, higher education, employment, higher income, and interaction with peers correlating with better knowledge scores (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). Although participants were well-informed about their diagnosis and medication (&gt;80%), understanding of disease causes (&lt;30%) and treatment prognosis and side effects (&lt;50%) was limited, and cost concerns affected 80.55%. Anxiety and depression were reported more among caregivers (46.64% and 13.8%) than patients (29.71% and 11.51%). While 84.85% adhered to the doctor\u2019s instructions, only 68.50% actively sought more CML information. Positive correlations were observed among KAP scores, indicating their interdependence (knowledge-attitude: <jats:italic toggle=\"yes\">R<\/jats:italic>\u2005=\u20050.397; knowledge-practice: <jats:italic toggle=\"yes\">R<\/jats:italic>\u2005=\u20050.598; attitude-practice: <jats:italic toggle=\"yes\">R<\/jats:italic>\u2005=\u20050.353; all <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). The findings underscore the importance of tailored education to fill knowledge gaps about CML and the need to address financial concerns and provide psychological support. The positive correlations among knowledge, attitudes, and practices emphasize the need for comprehensive interventions. In conclusion, this study highlights the importance of tailored education, addresses financial concerns, and provides emotional support for CML patients and caregivers in China, despite limitations such as convenience sampling and questionnaire design. Future research should evaluate the effectiveness of educational interventions and long-term outcomes to further enhance the overall well-being of this population.<\/jats:p>","DOI":"10.1097\/md.0000000000036498","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T21:16:29Z","timestamp":1702674989000},"page":"e36498","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of knowledge, attitudes, and practices of CML patients and their families toward TKI therapy in China"],"prefix":"10.1097","volume":"102","author":[{"given":"Lixiao","family":"Song","sequence":"first","affiliation":[{"name":"Department of Hematology, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University, Huai\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology, People\u2019s Hospital of Rizhao, Rizhao, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University, Huai\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shandong","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University, Huai\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banghe","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University, Huai\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University, Huai\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-7230","authenticated-orcid":false,"given":"Chunling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University, Huai\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am J Hematol"},{"key":"R2-20250504","first-page":"23","article-title":"Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib.","volume":"10","author":"Emole","year":"2016","journal-title":"Biologics"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(17)30232-6","article-title":"Epidemiological patterns of leukaemia in 184 countries: a population-based study.","volume":"5","author":"Miranda-Filho","year":"2018","journal-title":"Lancet Haematol"},{"issue":"Suppl 2","key":"R4-20250504","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update.","volume":"94","author":"Hoglund","year":"2015","journal-title":"Ann Hematol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.leukres.2010.12.034","article-title":"Estimation of CML incidence: disagreement between national cancer registry and health claims data system in Taiwan.","volume":"35","author":"Chang","year":"2011","journal-title":"Leuk Res"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.","volume":"54","author":"Chen","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12185-008-0230-0","article-title":"Chronic myeloid leukemia in Asia.","volume":"89","author":"Au","year":"2009","journal-title":"Int J Hematol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"443","DOI":"10.33145\/2304-8336-2020-25-443-455","article-title":"Chronic myeloid leukemia course in persons exposed to ionizing radiation as a result of the chornobyl accident.","volume":"25","author":"Dyagil","year":"2020","journal-title":"Probl Radiac Med Radiobiol"},{"key":"R9-20250504","first-page":"3760","article-title":"A review of risk factors for childhood leukemia.","volume":"20","author":"Jin","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ajim.22087","article-title":"Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions.","volume":"55","author":"Vlaanderen","year":"2012","journal-title":"Am J Ind Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/GO.21.00194","article-title":"Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the global burden of disease study 2019.","volume":"7","author":"Hu","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11899-019-0496-8","article-title":"Treatment-free remission in CML: the US perspective.","volume":"14","author":"Guru Murthy","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.japh.2017.01.004","article-title":"Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO.","volume":"57","author":"Haque","year":"2017","journal-title":"J Am Pharm Assoc (2003)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2012.082511","article-title":"Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.","volume":"99","author":"Noens","year":"2014","journal-title":"Haematologica"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2147\/PPA.S269355","article-title":"Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a systematic review.","volume":"15","author":"Tan","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3904\/kjim.2021.158","article-title":"Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia.","volume":"36","author":"Kim","year":"2021","journal-title":"Korean J Intern Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/1078155215608523","article-title":"Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.","volume":"22","author":"Lam","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2147\/PPA.S70712","article-title":"Chronic myeloid leukemia patients\u2019 adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians.","volume":"8","author":"Kekale","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1017\/S1478951513001260","article-title":"Lack of congruence between patients\u2019 and health professionals\u2019 perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: a qualitative study.","volume":"13","author":"Wu","year":"2015","journal-title":"Palliat Support Care"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2147\/PPA.S132894","article-title":"Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study.","volume":"11","author":"Tan","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e2021004","DOI":"10.4084\/mjhid.2021.004","article-title":"Social and financial barriers to optimum TKI treatment in patients with chronic myeloid leukemia-a knowledge-attitudes-practices study from India.","volume":"13","author":"Gupta","year":"2021","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/0284186X.2018.1518592","article-title":"Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross-sectional assessment of their distress and burden.","volume":"58","author":"Langenberg","year":"2019","journal-title":"Acta Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/0253717620946111","article-title":"Designing and conducting knowledge, attitude, and practice surveys in psychiatry: practical guidance.","volume":"42","author":"Andrade","year":"2020","journal-title":"Indian J Psychol Med"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology.","volume":"18","author":"Deininger","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11096-013-9867-8","article-title":"Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.","volume":"36","author":"Chen","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1340253","DOI":"10.1080\/16549716.2017.1340253","article-title":"Management of noma: practice competence and knowledge among healthcare workers in a rural district of Zambia.","volume":"10","author":"Ahlgren","year":"2017","journal-title":"Global Health Action"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"682020","DOI":"10.3389\/fphar.2021.682020","article-title":"A survey of pharmacogenomics testing among physicians, pharmacists, and researchers from China.","volume":"12","author":"Guo","year":"2021","journal-title":"Front Pharmacol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1007\/s00520-016-3344-6","article-title":"Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.","volume":"24","author":"Efficace","year":"2016","journal-title":"Support Care Cancer"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1177\/1078155218778106","article-title":"User acceptance of an app-based adherence intervention: perspectives from patients taking oral anticancer medications.","volume":"25","author":"Ali","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00432-018-2594-8","article-title":"Patients\u2019 and hematologists\u2019 concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.","volume":"144","author":"Jiang","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1186\/s12889-022-14596-6","article-title":"Emotional and behavioral attitudes of Tunisian youth towards childhood leukemia: health education and primary prevention in perspective.","volume":"22","author":"Maaoui","year":"2022","journal-title":"BMC Public Health"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2215-0366(18)30511-X","article-title":"Prevalence of mental disorders in China: a cross-sectional epidemiological study.","volume":"6","author":"Huang","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00520-012-1630-5","article-title":"Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.","volume":"21","author":"Phillips","year":"2013","journal-title":"Support Care Cancer"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1080\/10428194.2020.1842397","article-title":"Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.","volume":"62","author":"Shi","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"R36-20250504","first-page":"1","article-title":"Assessment of factors affecting the mental condition of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.","volume":"20","author":"Gibek","year":"2022","journal-title":"Psychiatr Pol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"12070","DOI":"10.1038\/s41598-019-48445-1","article-title":"An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States.","volume":"9","author":"Hao","year":"2019","journal-title":"Sci Rep"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.3390\/cancers13246269","article-title":"Potential to improve therapy of chronic myeloid leukemia (CML), especially for patients with older age: incidence, mortality, and survival rates of patients with CML in Switzerland from 1995 to 2017.","volume":"13","author":"Daskalakis","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:15:29Z","timestamp":1746321329000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":37,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036498","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]}}}